Journal article
Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Abstract
Importance: Owing to its anti-inflammatory properties and antiviral "in vitro" effect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), cannabidiol (CBD) has been proposed as a potential treatment for coronavirus disease 2019 (COVID-19). Objective: To investigate the safety and efficacy of CBD for treating patients with mild to moderate COVID-19. Design: Randomized, parallel-group, double-blind, placebo-controlled clinical …
Authors
Crippa JAS; Pacheco JC; Zuardi AW; Guimarães FS; Campos AC; de Lima Osório F; Loureiro SR; dos Santos RG; Souza JDS; Ushirohira JM
Journal
Cannabis and Cannabinoid Research, Vol. 7, No. 5, pp. 658–669
Publisher
Mary Ann Liebert
Publication Date
October 1, 2022
DOI
10.1089/can.2021.0093
ISSN
2578-5125